After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCI

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute (NCI) for the past 5 years, says that he will resign his post in April of this year. He will join IVAX Corporation (Miami), a manufacturer of generic drugs and IV drug delivery devices, where he plans to work on developing new drugs.

WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute(NCI) for the past 5 years, says that he will resign his postin April of this year. He will join IVAX Corporation (Miami),a manufacturer of generic drugs and IV drug delivery devices,where he plans to work on developing new drugs.

Dr. Broder first joined the NCI in 1972 as a researcher. He wasthe leader of a group that discovered the therapeutic benefitsof the antiretroviral agent zidovudine (Retrovir, AZT) in 1985.

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.